Skip to main content

Bioceres Crop Solutions Corp.

corporate_fare Company Profile

Bioceres Crop Solutions Corp.

BIOX·NASDAQ·Industrial Applications And Services·CIK 0001769484

Bioceres Crop Solutions Corp., together with its subsidiaries, develops and commercializes crop productivity solutions. It operates through Seed and Integrated Products, Crop Protection, and Crop Nutrition segments. The Seed and Integrated Products segment provides seed traits, germplasms, and seed treatment packs for healthier and higher yielding crops. The Crop Protection segment develops, produces, and markets Rizoderma, adjuvants, therapies, herbicides, insecticides, fungicides, and baits. The Crop Nutrition segment develops, produces, commercializes, and sells inoculants, bio-inductors, and biological and microgranulated fertilizers. It also offers HB4, a drought tolerant seed technology program. The company operates in Argentina, Brazil, North America, Europe, the Middle East, South America, the United States, and internationally. Bioceres Crop Solutions Corp. was founded in 2001 and is headquartered in Rosario, Argentina.

Bioceres Crop Solutions Corp. (NASDAQ:BIOX) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 21 items for BIOX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-11, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 13 rated 8 or above. Recent SEC coverage for BIOX spans 20-F, 6-K, SCHEDULE 13D/A.

Recent high-impact activity:

  • Bioceres Q1 Revenue Falls 22%, Net Loss Widens to $10.8M as Liquidity Tightens
  • Bioceres 20-F: Going-Concern Doubt, $263.9M FY26 Loss, $110.1M Noteholder Judgment
  • Bioceres Faces Summary Judgment Damages in Jasper Lake Ventures Lawsuit
  • Bioceres Gets Nasdaq Reprieve: Transfer to Capital Market and 180-Day Extension to Regain $1 Bid
  • Bioceres Returns to Positive Adjusted EBITDA in Q4, But Full-Year Loss Widens

Financial Snapshot

Fiscal year ended June 30, 2026
Revenue
$238.28M
Net Income
-$263.94M
Diluted EPS
-$4.06
Op. Cash Flow
$66.01M
Free Cash Flow
$64.96M
Gross Profit
$83.18M
Operating Income
-$23.41M
Cash & Equivalents
$7.22M
Total Debt
$59.98M
Debt / Equity
1.76×
Net Margin
-110.8%
Source: 20-F · filed 2026-10-30 · accession 0001104659-26-120726

Short Interest & Short Volume

1.71 days to cover

FINRA reported short interest of 458,064 shares in BIOX as of the October 30, 2026 settlement, a 46.3% decrease from the prior period — about 1.7 days to cover at its recent average daily volume. On November 20, 2026, 28.8% of BIOX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)458,064 shares as of October 30, 2026
Change vs prior period▼ 46.3%
Days to cover1.71 at avg daily volume of 268,438
Daily short volume (FINRA facilities)28.8% of 78,774 shares on November 20, 2026
5-day average short volume31.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Insider Transactions

BIOX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with B →
$0.175 +1.16% today
52-week range · as of 2026-10-30 $0.175 – $2.1
Market cap
$11.04M
Volume
130.2K (0.6× avg)
3-mo avg 216.3K
Live data · 2026-11-21 19:15 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BIOX - Latest Insights

BIOX
Nov 11, 2026, 5:51 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $0.2327
Real-time Price: $0.175 info
Change: -$0.0577 (-25%) info
Market Cap: $11.04M info
BIOX
Oct 30, 2026, 5:04 PM EDT
Filing Type: 20-F
Importance Score:
9
Price at Filing: $0.208
Real-time Price: $0.175 info
Change: -$0.033 (-16%) info
Market Cap: $11.04M info
BIOX
Sep 21, 2026, 6:09 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.346
Real-time Price: $0.175 info
Change: -$0.171 (-49%) info
Market Cap: $11.04M info
BIOX
Sep 15, 2026, 7:04 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.392
Real-time Price: $0.175 info
Change: -$0.217 (-55%) info
Market Cap: $11.04M info
BIOX
Sep 14, 2026, 6:43 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $0.4342
Real-time Price: $0.175 info
Change: -$0.2592 (-60%) info
Market Cap: $11.04M info
BIOX
Jul 07, 2026, 7:08 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $0.3294
Real-time Price: $0.175 info
Change: -$0.1544 (-47%) info
Market Cap: $11.04M info
BIOX
Jun 22, 2026, 6:04 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.3726
Real-time Price: $0.175 info
Change: -$0.1976 (-53%) info
Market Cap: $11.04M info
BIOX
Jun 01, 2026, 5:16 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $0.4837
Real-time Price: $0.175 info
Change: -$0.3087 (-64%) info
Market Cap: $11.04M info
BIOX
Jun 01, 2026, 10:16 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.4338
Real-time Price: $0.175 info
Change: -$0.2588 (-60%) info
Market Cap: $11.04M info
BIOX
May 12, 2026, 4:01 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.451
Real-time Price: $0.175 info
Change: -$0.276 (-61%) info
Market Cap: $11.04M info
BIOX
May 11, 2026, 5:00 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $0.557789
Real-time Price: $0.175 info
Change: -$0.382789 (-69%) info
Market Cap: $11.04M info
BIOX
Apr 28, 2026, 11:23 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $0.4862
Real-time Price: $0.175 info
Change: -$0.3112 (-64%) info
Market Cap: $11.04M info
BIOX
Apr 28, 2026, 11:11 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $0.5033
Real-time Price: $0.175 info
Change: -$0.3283 (-65%) info
Market Cap: $11.04M info
BIOX
Mar 24, 2026, 4:05 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $0.4097
Real-time Price: $0.175 info
Change: -$0.2347 (-57%) info
Market Cap: $11.04M info
BIOX
Mar 17, 2026, 9:16 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.4365
Real-time Price: $0.175 info
Change: -$0.2615 (-60%) info
Market Cap: $11.04M info
BIOX
Mar 13, 2026, 5:23 PM EDT
Filing Type: 6-K
Importance Score:
10
Price at Filing: $0.530
Real-time Price: $0.175 info
Change: -$0.355 (-67%) info
Market Cap: $11.04M info
BIOX
Mar 13, 2026, 4:15 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $0.5277
Real-time Price: $0.175 info
Change: -$0.3527 (-67%) info
Market Cap: $11.04M info
BIOX
Mar 05, 2026, 4:10 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $0.557
Real-time Price: $0.175 info
Change: -$0.382 (-69%) info
Market Cap: $11.04M info
BIOX
Feb 05, 2026, 5:49 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $0.5438
Real-time Price: $0.175 info
Change: -$0.3688 (-68%) info
Market Cap: $11.04M info
BIOX
Jan 21, 2026, 6:19 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Price at Filing: $1.22
Real-time Price: $0.175 info
Change: -$1.05 (-86%) info
Market Cap: $11.04M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets